Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

CDC removes unusual guidance to doctors about drug favored by Trump

Published 04/07/2020, 05:48 PM
Updated 04/07/2020, 06:11 PM
© Reuters. Laura Ng is pictured with her hydroxychloroquine prescription during the coronavirus disease (COVID-19) outbreak in Seattle

By Aram Roston and Marisa Taylor

WASHINGTON (Reuters) - The U.S. Centers for Disease Control and Prevention has removed from its website highly unusual guidance informing doctors on how to prescribe hydroxychloroquine and chloroquine, drugs recommended by President Donald Trump to treat the coronavirus.

The move comes three days after Reuters reported that the CDC published key dosing information involving the two antimalarial drugs based on unattributed anecdotes rather than peer-reviewed science.

Reuters also reported that the original guidance was crafted by the CDC after President Trump personally pressed federal regulatory and health officials to make the malaria drugs more widely available to treat the novel coronavirus, though the drugs in question had been untested for COVID-19.

Initially, the CDC webpage, titled Information for Clinicians on Therapeutic Options for Patients with COVID-19, had said: “Although optimal dosing and duration of hydroxychloroquine for treatment of COVID-19 are unknown, some U.S. clinicians have reported anecdotally” on several ways to prescribe the medication of COVID-19.

Medical specialists had told Reuters they were surprised by that language. “Why would CDC be publishing anecdotes?” asked Dr. Lynn Goldman, dean of the Milken Institute School of Public Health at George Washington University. “That doesn’t make sense. This is very unusual.”

Doctors and other health experts had further criticized the guidance as suggesting that doctors might prescribe the medications when it isn't established whether or not they are effective or harmful.

Now the CDC website no longer includes that information. Instead, its first sentence says: “There are no drugs or other therapeutics approved by the US Food and Drug Administration to prevent or treat COVID-19.”

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The updated, and shortened, guidance adds that “Hydroxychloroquine and chloroquine are under investigation in clinical trials” for use on coronavirus patients.

To read the new CDC guidance, click https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html

The CDC did not immediately respond to questions about the removal of the original guidance. In a statement, it had originally told Reuters it had crafted the guidance for doctors at the request of a coronavirus task force, which urged prompt action.

Jeffrey Flier, a former dean of Harvard Medical School who had criticized the original guidance, applauded the updated version, calling it “substantially improved.”

“It states the facts without in effect recommending that physicians prescribe the drugs despite a lack of adequate evidence,” Flier said.

The hydroxychloroquine debate has heated up and become more political as President Trump this weekend said he might want to take the drug himself.

Latest comments

the Orange racist buffoon schould take 20 per hour, that Will shut him up.
These are not normal times, CDC should have not changed the language.
I don't disagree, following red tape, normal FDA or CDC guidelines while thousands are dying w/o a cure is nonsense. They know plenty about this drug and they dibtraials all the time. Most drugs are only tested for 6 mo or less. There is something very wrong going on here.
because people are dying by the thousands. it seems
Tradeoffs (risk vs. survival) not absolute guarantees.
you have to take it with zinc in prescribed dose, if anyone is dying from it it's because they are self medicating. self medicating has a long history of adverse outcomes.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.